Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03179956 · ClinicalTrials.gov registry record · Early Phase 1
Impact of Ribociclib on Head and Neck Squamous Cell Cancer
A Early Phase 1 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT03179956 is a Early Phase 1 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 1 participants.
The verdict
NCT03179956, a Early Phase 1 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
A window of opportunity study which would allow brief treatment of HPV negative SCCHN with a CDK4/6 inhibitor, in the pre-operative setting, with biomarker analyses of pre and post treatment tissue. Given that the standard treatment for this population is surgical resection, this would not impact or alter standard therapy for this population. The goal will be to learn more about the alterations in pRB1 levels, as well as other signaling markers, in order to be able to eventually plan a biomarker driven treatment study.
Interventions
- DRUG Ribociclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-04-02 |
| Est. Completion | 2019-01-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03179956
The ClinicalTrials.gov registry entry for NCT03179956 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ribociclib is the first listed.
NCT03179956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03179956 about?
NCT03179956 is a clinical study titled "Impact of Ribociclib on Head and Neck Squamous Cell Cancer". A window of opportunity study which would allow brief treatment of HPV negative SCCHN with a CDK4/6 inhibitor, in the pre-operative setting, with biomarker analyses of pre and post treatment tissue. Given that the standard treatment for this population is surgical resection, this would not impact or...
What is the current status of trial NCT03179956?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2018-04-02. Estimated completion is 2019-01-10.
What interventions are being tested in trial NCT03179956?
The interventions under investigation include: Ribociclib (DRUG).
Who is sponsoring clinical trial NCT03179956?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.